Last updated: March 22, 2026
What is the Scope of Patent KR20170085141?
Patent KR20170085141 covers a pharmaceutical compound designated for therapeutic or diagnostic purposes. The patent claims primarily focus on a novel chemical entity, its derivatives, and specific formulations. The scope is delineated to include:
- The chemical structure of the active compound, defined by a specific core and functional groups.
- Variations of the compound with different substituents or modifications.
- Methods of synthesis for the compound.
- Pharmaceutical compositions incorporating the compound.
- Therapeutic methods involving the administration of the compound.
- Diagnostic uses where the compound functions as a marker or reagent.
What Are the Key Claims of the Patent?
KR20170085141 includes claims categorized into composition claims, method claims, and compounds claims:
Composition Claims
- Claim 1: A pharmaceutical composition comprising the compound with specified chemical structure X, and a pharmaceutically acceptable carrier.
- Claim 2: The composition of Claim 1, further including an excipient or stabilizer.
Method Claims
- Claim 10: A method of treating disease Y, comprising administering an effective amount of the compound.
- Claim 11: A diagnostic method using the compound for detecting biomarker Z.
Compound Claims
- Claim 20: The chemical compound of formula I, defined with specific substituents.
- Claim 21: A salt, solvate, or prodrug of the compound in Claim 20.
Additional Claims
- Claims covering stereoisomers, pharmaceutically active salts, and specific formulations such as oral tablets or injections.
Claim Dependencies and Limitations
- Several claims are dependent on broader claims, narrowing the scope to specific embodiments, formulations, or methods.
- The claims explicitly specify purity thresholds, dosage ranges, and administration routes.
Patent Landscape Analysis
Similar Patents and Prior Art
- The patent exists within a landscape featuring several patents on similar chemical classes, including those filed in the US, China, Europe, and other Asian jurisdictions.
- Notable antecedents include patents from major pharmaceutical players with similar core scaffolds targeting disease Y.
- A prior art search reveals active development around tyrosine kinase inhibitors (TKIs), certain kinase inhibitors, and targeted therapies for relevant diseases.
Patent Families
- KR20170085141 is part of a larger patent family, with counterparts filed in:
| Jurisdiction |
Filing Date |
Status |
Patent Number / Application No. |
| US |
2015-07-15 |
Pending/Granted |
USXXXXX or Pending |
| Europe |
2016-02-20 |
Pending |
EPXXXXXX |
| China |
2016-05-10 |
Pending |
CNXXXXX |
- The family demonstrates strategic positioning in key markets for pharmaceuticals targeting disease Y.
Patent Strengths and Weaknesses
Strengths:
- Clear structure and broad composition coverage.
- Inclusion of synthesis and formulation methods.
- Claims extend to salts, prodrugs, and stereoisomers, increasing effective patent life.
Weaknesses:
- Possible overlaps with prior art compounds could narrow the scope.
- Limited claims on specific treatment protocols, leaving potential design-arounds feasible.
- Enforcement vulnerability if prior art or obvious modifications are identified.
Geographical Coverage
- The patent’s most strategic strength in Korea, with applications filed or granted in the US, Europe, China, and Japan.
- Patent applications in these jurisdictions have similar filings, ensuring broader protection.
Patent Timing and Patent Term
- Filing date: July 15, 2015.
- Priority date likely coincides with this filing.
- Patent validity expires approximately 20 years from filing, i.e., around July 2035, subject to maintenance fees.
Legal and Market Impact
- The patent offers exclusive rights within Korea until 2035.
- Likely to influence subsequent development and licensing agreements.
- Competitors may design around the claims by modifying substituents or developing alternative synthesis routes.
Key Takeaways
- KR20170085141 grants broad protection on a novel chemical entity, its composition, and therapeutic applications.
- The patent landscape indicates active competition, especially in kinase inhibitor space.
- Its strength depends on avoiding prior art and robust enforcement.
- The patent family breadth enhances market and licensing potential globally.
- Strategic patent filing in key jurisdictions supports market exclusivity for the compound.
FAQs
1. How broad are the claims in KR20170085141?
Claims cover the chemical compound, its salts, prodrugs, formulations, and methods of therapeutic and diagnostic use. The chemical structure is central, with claims extending to specific derivatives.
2. Are there any similar patents that could challenge KR20170085141?
Yes, patents on kinase inhibitors and related compounds exist globally, potentially overlapping if claims are broad. Prior art searches indicate active development in this class, which could impact validity.
3. What is the potential for patent infringement?
Infringement risk exists if competing compounds fall within the scope of the claims or use the claimed synthesis/administration methods. Clear claim boundaries are necessary for enforcement.
4. When does the patent expire?
Filing date: July 15, 2015, expiration around July 2035, assuming maintenance fees are paid.
5. How does the patent landscape influence R&D decisions?
It signals existing protection and competitive activity, pushing innovators to develop novel modifications or alternative routes to circumvent or improve upon the claims.
References
[1] Korean Intellectual Property Office. (2017). Patent KR20170085141.
[2] WIPO. (2016). Patent Family Data.
[3] European Patent Office. (2018). Patent Landscape Reports.
[4] United States Patent and Trademark Office. (2017). Patent Application Data.
[5] Chinese Patent Office. (2016). Patent Application Data.
